TY - JOUR
T1 - The 2-Year Course of Internet Addiction Among a Japanese Adolescent Psychiatric Clinic Sample with Autism Spectrum Disorder and/or Attention-Deficit Hyperactivity Disorder
AU - So, Ryuhei
AU - Makino, Kazunori
AU - Hirota, Tomoya
AU - Fujiwara, Masaki
AU - Ocho, Kozo
AU - Ikeda, Shin
AU - Tsubouchi, Shouko
AU - Inagakip, Masatoshi
N1 - Funding Information:
KM, KO, SI, and ST have no conflict of interest to declare. RS has received professional fees from Igaku-shoin Co. Ltd., Kagaku-hyoronsha Co. Ltd., Medical Review Co. Ltd., and Otsuka Pharmaceutical Co. Ltd., outside the submitted work. TH has received professional fees for speaking at the symposia of Otsuka Pharmaceutical Co., Ltd.. MF has received professional fees from Mochida Pharmaceutical Co. Ltd., Eli Lilly Japan K.K., Sumitomo Dainippon Pharma Co. Ltd., Sentan Igaku-sha Ltd., Igaku-Shoin Ltd., and Iyaku (Medicine and Drug) Journal Co. Ltd. outside the submitted work. MI declares that he has received grants from Novartis. He has received lecture fees from Meiji, Mochida, Takeda, Novartis, Yoshitomi, Pfizer, Eisai, Otsuka, and MSD and personal fees from Technomics. Institution of MI received grant or research support from Eisai, Astellas, Dainippon-Sumitomo, Pfizer, Daiichi-Sankyo, Takeda, and MSD outside the submitted work. The institution to which MF belongs has received grants and research support from Eisai Co. Ltd., Mochida Pharmaceutical Co. Ltd., Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., GlaxoSmithKline K. K., Shionogi & Co., Sumitomo Dainippon Pharma Co. Ltd., Jansen Pharmaceutical K. K., Pfizer Japan Inc., MSD K. K., Yoshitomiyakuhin Corporation, Daiichi Sankyo Co. Ltd., Meiji Seika Pharma Co. Ltd., Tsumura & Co., AbbVie, Ono Pharmaceutical Co. Ltd., and Eli Lilly Japan K. K.
Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Internet addiction (IA) has been reported as prevalent in adolescents with autism spectrum disorders (ASD) and attention-deficit hyperactivity disorder (ADHD). However, the course of IA in this population has not been elucidated. The authors performed a 2-year follow-up study including 89 out of 132 adolescents with ASD and/or ADHD in a psychiatric clinical setting who participated in the original cross-sectional study assessing IA prevalence. Within this sample of participants from both the original and the follow-up study, results showed a 2-year IA remission and incidence rate of 60% and 5%, respectively. Our findings imply that the course of IA in psychiatric populations with ASD and/or ADHD might be similar to reports from previous studies with general adolescent populations.
AB - Internet addiction (IA) has been reported as prevalent in adolescents with autism spectrum disorders (ASD) and attention-deficit hyperactivity disorder (ADHD). However, the course of IA in this population has not been elucidated. The authors performed a 2-year follow-up study including 89 out of 132 adolescents with ASD and/or ADHD in a psychiatric clinical setting who participated in the original cross-sectional study assessing IA prevalence. Within this sample of participants from both the original and the follow-up study, results showed a 2-year IA remission and incidence rate of 60% and 5%, respectively. Our findings imply that the course of IA in psychiatric populations with ASD and/or ADHD might be similar to reports from previous studies with general adolescent populations.
KW - Attention-deficit hyperactivity disorder
KW - Autism spectrum disorder
KW - Health-related quality of life
KW - Internet addiction
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=85070937239&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85070937239&partnerID=8YFLogxK
U2 - 10.1007/s10803-019-04169-9
DO - 10.1007/s10803-019-04169-9
M3 - Article
C2 - 31410697
AN - SCOPUS:85070937239
VL - 49
SP - 4515
EP - 4522
JO - Journal of Autism and Developmental Disorders
JF - Journal of Autism and Developmental Disorders
SN - 0162-3257
IS - 11
ER -